NCT06346067Phase 3Active not recruiting

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Study sponsor: Erasca, Inc. · ERAS

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2028-04Estimated
Enrollment · participants78Actual
Source updated2026-02-27Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 3 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 470 participants (planned). After: 78 participants (actual).

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview